Evidence map›Paper›PMID 40266134›Full record

ArticleVaccines2025

Awareness and Knowledge About Preventive Vaccinations Among Patients with Hematological Malignancies.

Marta Morawska, Marta Masternak, Norbert Grząśko, Ewa Lech-Marańda, Tomasz Wróbel, Sebastian Giebel, Krzysztof Tomasiewicz, Krzysztof Giannopoulos

Abstract read
In one paragraph

Article in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Marta MorawskaDepartment of Experimental Hematooncology, Medical University of Lublin, 20-093 Lublin, Poland.ORCID 0000-0001-6836-2903
Marta MasternakDepartment of Experimental Hematooncology, Medical University of Lublin, 20-093 Lublin, Poland.
Norbert GrząśkoDepartment of Experimental Hematooncology, Medical University of Lublin, 20-093 Lublin, Poland.ORCID 0000-0001-7727-4307
Ewa Lech-MarańdaDepartment of Hematology, Institute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland.
Tomasz WróbelClinical Department of Hematology, Cell Therapies and Internal Diseases, Wroclaw Medical University, 50-367 Wroclaw, Poland.
Sebastian GiebelDepartment of Bone Marrow Transplantation and OncoHematology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, 44-102 Gliwice, Poland.
Krzysztof TomasiewiczDepartment and Clinic of Infectious Diseases and Hepatology, USK-1, Medical University of Lublin, 20-090 Lublin, Poland.
Krzysztof GiannopoulosDepartment of Experimental Hematooncology, Medical University of Lublin, 20-093 Lublin, Poland.ORCID 0000-0003-0135-4030

Funding

New Generation Hematology Association KE-0254/345/2019
6 · The paper itself

Abstract

backgroundPatients with hematological malignancies, including multiple myeloma (MM) and chronic lymphocytic leukemia (CLL), are at an increased risk of severe infections due to both disease- and therapy-related immunosuppression. This cross-sectional study evaluated awareness of infection risks and vaccination uptake among 150 adults with various hematological malignancies from major Polish centers.

methodsAll participants completed a 30-item questionnaire capturing demographic data, treatment history, infection frequency, and vaccination attitude. Statistical analyses utilized Chi-square and Fisher's exact tests, with

resultsRespondents had a median age of 57 years (range, 30-79), and 65.3% were female. MM was the most common diagnosis (64.7%), followed by CLL (4.0%) and other hematological malignancies (31.3%). Nearly all participants (99.3%) acknowledged their increased susceptibility to infections. Frequent infections (≥2 in the past 6 months) were significantly associated with transfusion dependency (

conclusionsOur findings underscore the critical need for targeted educational strategies and robust vaccination guidelines in this immunocompromised population. Enhanced patient education and timely implementation of tailored vaccination regimens could reduce infection-related morbidity and improve the tolerability of cancer treatments.

Indexed as

COVID-19hematological malignanciesmultiple myelomavaccinationvaccine hesitancy

Identifiers

PMID40266134
PMCPMC11945929

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.